The CDK7 inhibitor CT7001 (Samuraciclib) targets proliferation pathways to inhibit advanced prostate cancer

Added 46 days ago (30.06.2022)
Authors: Constantin, T. A., Varela-Carver, A., Greenland, K. K., Serrano de Almeida, G., Penfold, L., Ang, S., Ormrod, A., Ainscow, E. K., Bahl, A. K., Carling, D., Fuchter, M. J., Ali, S., Bevan, C. L.
Source: bioRxiv
Read article